Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

320 LANTHANUM
Other
Abdominal pain (17%)
Myalgia/Myositis/Myopathy/Myotoxicity
(2005): Finn WF+, Curr Med Res Opin 21(5), 657 (20.8%)
LAPATINIB*
Trade name: Tykerb (GSK)
Indications: Breast cancer
Category: Epidermal growth factor receptor (EGFR); Tyrosine
kinase inhibitor
Half-life: 24 hours
Clinically important, potentially hazardous interactions
with: atazanavir, carbamazepine*, clarithromycin, CYP3A4
inhibitors, dexamethasone*, grapefruit juice, indinavir,
itraconazole, nefazodone, nelfinavir, phenobarbital*, phenytoin*,
rifabutin*, rifampin*, rifapentin*, ritonavir, saquinavir, St John’s
wort*, telithromycin, voriconazole. The concomitant use of
strong CYP3A4 inducers should be avoided
*Note: Lapitinib is used in conjunction with capecitabine
Reactions
Skin
Hand–foot syndrome (53%)
Inflammation (15%)
Rash (sic) (44%)
(2006): Nelson MH+, Ann Pharmacother 40(2), 261
Xerosis (10%)
Mucosal
Stomatitis (14%)
Hair
Depigmentation (21%)
Other
Abdominal pain (15%)
Anorexia (24%)
Pain (extremities) (12%)
LARONIDASE
Synonyms: TNX-901; E25; IGE-025; rhuMAb-E25
Trade name: Aldurazyme (Genzyme)
Indications: Mucopolysaccharidosis I
Category: Enzyme
Half-life: 1.5–3.6 hours
Clinically important, potentially hazardous interactions
with: None
Reactions
Skin
Facial edema (9%)
Peripheral edema (9%)
Rash (sic) (36%)
Urticaria
Other
Anaphylactoid reactions/Anaphylaxis
Application-site pain (9%)
Application-site reactions (18%)
Fever
Hypersensitivity
Upper respiratory infection
LATANOPROST
Trade name: Xalatan (Pfizer)
Indications: Glaucoma
Category: Prostaglandin analog
Half-life: 17 minutes
Reactions
Skin
Allergic reactions (sic) (1.1%)
Eczema (0.7%)
Erythema
(2005): Ross EK+, JAmAcadDermatol53(6), 1095
Facial rash
(1997): Rowe JA+, Am J Ophthalmol 124, 683
Hyperhidrosis
(2005): Kumar H+, Clin Experiment Ophthalmol 33(6), 675
Irritation
(1999): Hejkal TW+, Semin Ophthalmol 14, 114
Pruritus (0.2%)
(2005): Ross EK+, JAmAcadDermatol53(6), 1095
(1997): Crowe MA, Puyallup, WA (from Internet) (observation)
Rash (sic) (1–10%)
Toxic epidermal necrolysis
(2005): Florez A+, JAmAcadDermatol53(5), 909 (with timolol
&dorzolamide)
Eyes
Blepharitis (0.4%)
Choroidal detachment
(2005): Pathanapitoon K+, J Med Assoc Thai 88(8), 1134
Conjunctival hyperemia
(2005): Chiselita D+, Oftalmologia 49(3), 39
(2005): Konstas AG+, Ophthalmology 112(2), 262
(2003): Stewart WC+, Am J Ophthalmol 135(3), 314
(2002): Eisenberg DL+, Surv Ophthalmol 47 Suppl 1, S105
(2001): DuBiner H+, Surv Opthalmol 45(Suppl 4), S353–60
(2001): Gandolfi S+, Adv Ther 18(3), 110
Eyelashes – hypertrichosis
(2006): Elgin U+, Eur J Ophthalmol 16(2), 247
(2006): Inoue K+, Nippon Ganka Gakkai Zasshi 110(8), 581
(2005): Casson RJ+, Am J Ophthalmol 139(5), 932
(2005): Chiselita D+, Oftalmologia 49(3), 39
(2004): Tosti A+, JAmAcadDermatol51(5 Suppl), S149
(2003): Costagliola C+, Expert Opin Pharmacother 4(10), 1775
(2003): Herndon LW+, Am J Ophthalmol 135(5), 713
(2003): Noecker RS+, Am J Ophthalmol 135(1), 55
(2002): Eisenberg DL+, Surv Ophthalmol 47(Suppl 1), S105
(2002): Johnstone MA+, Surv Ophthalmol 47(Suppl 1), S185
(2002): Sugimoto M+, Can J Ophthalmol 37(6), 342
(2001): Demitsu T+, JAmAcadDermatol44, 721 (77%)
(2001): Strober BE+, Cutis 67, 109
(1997): Johnstone MA, Am J Ophthalmol 124, 544
Eyelashes – pigmentation
(2006): Inoue K+, Nippon Ganka Gakkai Zasshi 110(8), 581
(2005): Chiselita D+, Oftalmologia 49(3), 39
(2004): Grierson I+, Jpn J Ophthalmol 48(6), 602
(2003): Costagliola C+, Expert Opin Pharmacother 4(10), 1775
(1999): Hejkal TW+, Semin Ophthalmol 14, 114
(1998): Reynolds A+, Eye 12, 741
(1997): Johnstone MA, Am J Ophthalmol 124, 544
(1997): Wand M, Arch Ophthalmol 115, 1206